Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 FDA PRIORITY REVIEW OF NEW DRUG APPLICATION (NDA) FOR ZIFTOMENIB IN ADULTS WITH R/R NPM1-M AML WITH PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE SET FOR NOVEMBER 30, 2025   FULLY ENGAGED IN COMMERCIAL READINESS ACTIVITIES IN ALIGNMENT WITH REGULATORY REVIEW TIMELINE   KOMET-017-IC (INTENSIVE CHEMOTHERAPY) AND NIC (NON-INTENSIVE CHEMOTHERAPY) PHASE 3 STUDIES IN NEWLY DIAGNOSED AML ON TRACK TO START IN 2H 2025   THREE CLINICAL ABSTRACTS FROM KURA'S FARNESYL TRANSFERASE INHIBITORS (FTI) DEVELOPMENT PROGRAM ACCEPTED FOR PRESENTATION AT THE 2025 ESMO CONGRESS   $630.7 MILLION IN PRO FORMA CASH, TOGETHER WITH ANTICIPATED COLLABORATION AGREEMENT PAYMENTS, EXPECTED TO SUPPORT ZIFTOMENIB COMMERCIALIZATION THROUGH THE FRONTLINE AML COMBINATION SETTING   MANAGEMENT TO HOST WEBCAST AND CONFERENCE CALL TODAY AT 4:30 P.M. ET  SAN DIEGO, AUG. 07, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY REPORTED SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDED A CORPORATE UPDATE.

KURA ONCOLOGY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

SAN DIEGO, AUG. 04, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (THE COMPANY) (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT ON AUGUST 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NONSTATUTORY STOCK OPTIONS TO PURCHASE 646,700 SHARES OF COMMON STOCK TO THIRTY-FIVE (35) NEW EMPLOYEES UNDER THE COMPANY'S 2023 INDUCEMENT OPTION PLAN, AS AMENDED. THE COMPENSATION COMMITTEE APPROVED THE STOCK OPTIONS AS AN INDUCEMENT MATERIAL TO SUCH EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

SAN DIEGO, JULY 31, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED IT WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AFTER THE CLOSE OF U.S. FINANCIAL MARKETS ON THURSDAY, AUGUST 7, 2025. KURA'S MANAGEMENT WILL HOST A WEBCAST AND CONFERENCE CALL AT 4:30 P.M. ET / 1:30 P.M. PT TO DISCUSS THE FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

KURA ONCOLOGY TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS

SAN DIEGO, JULY 03, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (THE COMPANY) (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT ON JULY 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NONSTATUTORY STOCK OPTIONS TO PURCHASE 141,750 SHARES OF COMMON STOCK TO EIGHT (8) NEW EMPLOYEES UNDER THE COMPANY'S 2023 INDUCEMENT OPTION PLAN, AS AMENDED. THE COMPENSATION COMMITTEE APPROVED THE STOCK OPTIONS AS AN INDUCEMENT MATERIAL TO SUCH EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

 ENCOURAGING CLINICAL ACTIVITY WITH DEEP RESPONSES DEMONSTRATED IN THE KOMET-007 TRIAL WITH THE COMBINATION OF 600 MG ZIFTOMENIB WITH 7+3 IN NEWLY DIAGNOSED PATIENTS WITH NPM1-M AND KMT2A-R AML

KURA ONCOLOGY AND KYOWA KIRIN REPORT POSITIVE UPDATED COMBINATION DATA FOR ZIFTOMENIB IN NEWLY DIAGNOSED AML AT 2025 EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS

SAN DIEGO, JUNE 06, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (THE COMPANY) (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT ON JUNE 2, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NONSTATUTORY STOCK OPTIONS TO PURCHASE 79,200 SHARES OF COMMON STOCK TO FIVE (5) NEW EMPLOYEES UNDER THE COMPANY'S 2023 INDUCEMENT OPTION PLAN, AS AMENDED. THE COMPENSATION COMMITTEE APPROVED THE STOCK OPTIONS AS AN INDUCEMENT MATERIAL TO SUCH EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

 CR/CRH RATE OF 23% IN PIVOTAL PH 2 COHORT OF R/R NPM1-M AML PATIENTS   CONSISTENT EFFICACY WITH COMPARABLE CR/CRH RATES AND CLINICALLY MEANINGFUL MRD-NEGATIVE RESPONSES ACROSS PRE-SPECIFIED SUBGROUPS, REGARDLESS OF PRIOR HSCT, PRIOR VENETOCLAX, OR FLT3/IDH CO-MUTATIONS   FAVORABLE SAFETY AND TOLERABILITY PROFILE IN HEAVILY PRE-TREATED PATIENTS: LIMITED MYELOSUPPRESSION; NO CLINICALLY MEANINGFUL QTC PROLONGATION; 3% OF PATIENTS DISCONTINUED DUE TO TREATMENT-RELATED ADVERSE EVENTS   POTENTIAL FIRST APPROVAL OF A ONCE-DAILY, ORAL MENIN INHIBITOR FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY NPM1-MUTATED AML WITH PRIORITY REVIEW AND A PDUFA TARGET ACTION DATE OF NOVEMBER 30, 2025  KURA ONCOLOGYTO HOST VIRTUAL INVESTOR EVENT TODAY AT 7:30PM ET / 4:30PM PT SAN DIEGO AND TOKYO, JUNE 02, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA, KURA) AND KYOWA KIRIN CO., LTD. (TSE: 4151, KYOWA KIRIN) ANNOUNCED THE PRESENTATION OF POSITIVE PIVOTAL RESULTS FROM THE KOMET-001 PHASE 2 REGISTRATION-DIRECTED TRIAL OF ZIFTOMENIB, A ONCE-DAILY, ORAL INVESTIGATIONAL MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NPM1-MUTANT (NPM1-M) ACUTE MYELOID LEUKEMIA (AML) IN AN ORAL SESSION TODAY AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING BEING HELD IN CHICAGO, IL FROM MAY 30 - JUNE 3, 2025.

KURA ONCOLOGY AND KYOWA KIRIN REPORT POSITIVE PIVOTAL ZIFTOMENIB MONOTHERAPY DATA AT 2025 ASCO ANNUAL MEETING

 NEW DRUG APPLICATION BASED ON POSITIVE RESULTS FROM THE PHASE 2 KOMET-001 TRIAL   FDA ASSIGNS A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF NOVEMBER 30, 2025   POTENTIAL FIRST APPROVAL OF A MENIN INHIBITOR FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY AML WITH AN NPM1 MUTATION  SAN DIEGO AND TOKYO, JUNE 01, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA, KURA) AND KYOWA KIRIN CO., LTD. (TSE: 4151, KYOWA KIRIN) TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED KURA'S NEW DRUG APPLICATION (NDA) SEEKING FULL APPROVAL FOR ZIFTOMENIB AS A TREATMENT FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) WITH A NUCLEOPHOSMIN 1 (NPM1) MUTATION.

KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR ZIFTOMENIB IN ADULTS WITH RELAPSED OR REFRACTORY NPM1-MUTANT AML

 RESULTS FROM KOMET-001 REGISTRATION-DIRECTED TRIAL OF ZIFTOMENIB IN R/R NPM1-M AML PATIENTS SELECTED FOR ORAL PRESENTATION ON MONDAY, JUNE 2ND 

KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE PIVOTAL MONOTHERAPY DATA FOR ZIFTOMENIB IN ORAL PRESENTATION AT THE 2025 ASCO ANNUAL MEETING

SAN DIEGO, MAY 20, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (THE COMPANY) (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT MANAGEMENT IS SCHEDULED TO PARTICIPATE IN THREE UPCOMING INVESTOR CONFERENCES:

Kura Oncology, Inc.

KURA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Kura Oncology, Inc.

KURA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

KURA